Epidemiological Markers in Adult Glial Tumors: A Single-Center Experience and The Utility of the Classification System
Eyüp BAYATLI1,Bora TETİK2,Murat BÜYÜKTEPE1,Nurhan TOKDEMİR1,Yahya Efe GÜNER3,Yıldız GÜNEY4,Hasan Çağlar UĞUR1
1Deparment of Neurosurgery, Ankara University Faculty of Medicine, Ankara-Turkey
2Deparment of Neurosurgery, Inonu University Faculty of Medicine, Malatya-Turkey
3Deparment of Neurosurgery, Yuksek İhtisas University Faculty of Medicine, Ankara-Turkey
4Deparment of Radiation Oncology, Yüksek İhtisas University, Ankara Memorial Hospital, Ankara-Turkey
DOI : 10.5505/tjo.2021.3441 OBJECTIVE
This study aimed to investigate the etiology of gliomas and determine the utility of the World Health Organization (WHO) classification of central nervous system tumors.

Patients aged ≥18 years who underwent surgery or were followed up for glial tumors between January 2017 and January 2020 and whose pathology reports indicated grade II-IV gliomas were included in the study. Patients with missing data, pathology results incompatible with grade II-IV gliomas, and unavailable standard molecular/genetic tumor profiles were excluded from the study.

The results of the standard histopathological and molecular/genetic analyses were evaluated retrospectively without any additional examinations. Data from 259 patients were evaluated. Of these, 8 patients who did not meet the criteria for glioma pathology and 27 patients with not otherwise specified molecular pathological examination results were excluded from the study. Patients were evaluated in detail regarding demographic and admission data, pathology analysis, potential risk factors, and survival results.

Many factors, particularly high blood glucose levels, sedentary lifestyle, and radiofrequency electromagnetic field exposure, appear to have a relationship with glioma etiology. There is a major heterogeneity and lack of standardized efficient laboratory procedures that may interfere with reliable standard molecular results. "False positive" molecular markers consist a major classification issue and methods that reflect the requirements of the WHO classification may themselves be inadequate to establish a profile with adequate sensitivity. The development of more practical and accessible methods in addition to standardized, rapid, and reliable methods for testing multiple markers at an acceptable cost is urgently needed. Keywords : Classification; epidemiology; glioma; molecular; tumor